ImmunoGen rated at sector perform by RBC

RBC Capital Markets analyst Jason Kantor rated ImmunoGen, Inc. at sector perform, speculative risk. The company is relatively low risk, with its low cash burn and diversified portfolio of proprietary and partnered programs. The analyst expects ImmunoGen and its partners to advance their current clinical programs and possibly start one or more new clinical programs over the next 12 months. Shares of the Cambridge, Mass.-based pharmaceutical company were down 11 cents, or 3.59%, at $2.95, on volume of 106,410 shares versus the three-month running average of 235,278 shares. (Nasdaq: IMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.